Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Assets (2016 - 2025)

IGC Pharma has reported Assets over the past 15 years, most recently at $9.7 million for Q3 2025.

  • Quarterly Assets fell 6.04% to $9.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $9.7 million through Sep 2025, down 6.04% year-over-year, with the annual reading at $8.7 million for FY2025, 11.66% down from the prior year.
  • Assets was $9.7 million for Q3 2025 at IGC Pharma, up from $7.9 million in the prior quarter.
  • Over five years, Assets peaked at $35.9 million in Q1 2021 and troughed at $7.9 million in Q2 2025.
  • The 5-year median for Assets is $16.5 million (2023), against an average of $18.7 million.
  • Year-over-year, Assets increased 29.49% in 2021 and then tumbled 43.9% in 2023.
  • A 5-year view of Assets shows it stood at $31.3 million in 2021, then crashed by 35.85% to $20.1 million in 2022, then tumbled by 43.9% to $11.3 million in 2023, then decreased by 19.37% to $9.1 million in 2024, then increased by 7.33% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Assets are $9.7 million (Q3 2025), $7.9 million (Q2 2025), and $8.7 million (Q1 2025).